The 23andMe Health + Ancestry Service experience.

The 23andMe experience is designed to be user-friendly. Individuals interested in viewing their health and ancestry through the lens of their personal genetics use a home-based saliva collection kit to provide their saliva sample. In exchange, they receive access to more than 75 genetic reports through a private and secure online account from the comfort of their homes.


How it works

1. Obtain and register a kit

2. Submit saliva sample

3. Explore results

4. Participate in research

Obtain and register a kit.

Customers purchase their kits online at or through one of our authorized retailers without medical requisition. They have the option of two different services: 23andMe Health + Ancestry Service ($199) or 23andMe Ancestry Service ($99). Prior to purchasing the Health + Ancestry Service, they are provided with important test information.

Customers create their accounts and register their kits. They are able to consent to participate in research, to allow 23andMe to store their sample and to opt-in to receive Genetic Health Risk reports. They are required to complete an educational module prior to viewing their results. Sensitive reports, such as Late-Onset Alzheimer’s Disease and Parkinson’s Disease, require additional opt-ins. Customers are encouraged to speak with their healthcare providers or meet with a genetic counselor prior to testing.

Learn more about the opt-in process.

Submit saliva sample.

Customers submit saliva samples from their homes by following a simple set of step-by-step instructions. 23andMe’s DNA collection kit is FDA-cleared for use with our Genetic Health Risk* and Carrier Status* reports and manufactured in accordance with FDA’s current Good Manufacturing Practice regulations.

The saliva sample is mailed to the lab in pre-paid packaging. All samples are processed using custom Illumina HumanOmniExpress-24 genotyping chips. This technology allows the identification of specific genetic variants that can be informative about the customer’s health and ancestry.

meets fda requirements

Genetic Health Risks*

5+ reports

  • 5+ reports including:
  • Hereditary Thrombophilia
  • Late-Onset Alzheimer's Disease
  • Parkinson's Disease
  • sample report
meets fda requirements

Carrier Status*

40+ reports

  • 40+ reports including:
  • Cystic Fibrosis
  • Sickle Cell Anemia
  • Hereditary Hearing Loss
  • sample report


5 reports

  • 5 reports including:
  • Ancestry Composition
  • Maternal & Paternal Haplogroups
  • Neanderthal Ancestry
  • sample report


5+ reports

  • 5+ reports including:
  • Deep Sleep
  • Lactose Intolerance
  • Genetic Weight
  • sample report


15+ reports

  • 15+ reports including:
  • Hair Loss
  • Sweet vs. Salty
  • Unibrow
  • sample report

Explore results.

Depending on which service they have selected, customers can gain access to more than 75 interactive reports*, online tools (Inheritance Tracing, Share and Compare and DNA Relatives), education modules and other helpful resources, including the 23andMe Customer Care team.

Customers are encouraged to share their results with their healthcare provider. It may be advisable under certain circumstances to refer patients to a genetic counselor. They can also locate a genetic counselor near them through the National Society of Genetic Counselors.

Genetic counselors can help navigate common questions, such as:

  • What can be learned from genetic testing?
  • What are the risks and benefits of genetic testing?
  • Are there diseases that run in the family that would make this test or another genetic test more appropriate?
  • How do I best handle potentially distressing genetic information?
  • How do my results affect my family members?

View all reports.

Participate in research.

~85% of our customers choose to participate in 23andMe research by answering online survey questions. On average, a customer who opts in to research contributes to more than 200 studies on topics that range from Parkinson’s disease and lupus to asthma and more. By participating in online surveys and allowing researchers to combine their aggregated, de-identified genetic data with millions of other data points, customers can help drive scientific and medical discoveries forward. See our list of publications here.

We have also collaborated with leading researchers in academia and pharma around the world to improve understanding of the underlying genetics of certain diseases, which could lead to better diagnostics and treatments. Our past research communities include lupus, inflammatory bowel disease (IBD), pain and fertility, among others. Although enrollment for these is now closed, our community research efforts continue. 23andMe is currently enrolling participants for the following studies:


Questions? Contact us at

* The 23andMe PGS test uses qualitative genotyping to detect clinically relevant variants in the genomic DNA of adults from saliva collected using an FDA-cleared collection device (Oragene·DX model OGD-500.001) for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. The relevance of each report varies based on ethnicity. Each Genetic Health Risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. These reports are intended to provide genetic information that can be used to inform lifestyle decisions and conversations with healthcare professionals, but are not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication or how much of a medication you should take. Any diagnostic or treatment decisions should be based on testing or other information deemed appropriate by a healthcare professional. Our Carrier Status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future or anything about the health of your fetus, or your newborn child’s risk of developing a particular disease later in life. For Gaucher Disease Type 1, we provide a single report that includes information on both carrier status and genetic health risk. The Late-Onset Alzheimer’s Disease Genetic Health Risk report is indicated for reporting of the ε4 variant in the APOE gene and describes if a person has a variant associated with an increased risk of developing late-onset Alzheimer’s disease. The ε4 variant included in this report is found and has been studied in many ethnicities. Detailed risk estimates have been studied the most in people of European descent. The Parkinson’s Disease Genetic Health Risk report (i) is indicated for reporting of the G2019S variant in the LRRK2 gene, and the N370S variant in the GBA gene, (ii) describes if a person has variants associated with an increased risk of developing Parkinson’s disease and (iii) is most relevant for people of European, Ashkenazi Jewish and North African Berber descent. The Hereditary Thrombophilia Genetic Health Risk report (i) is indicated for reporting of the Factor V Leiden variant in the F5 gene, and the Prothrombin G20210A variant in the F2 gene, (ii) describes if a person has variants associated with a higher risk of developing harmful blood clots and (iii) is most relevant for people of European descent. The Cystic Fibrosis Carrier Status test is indicated for the detection of 28 variants in the CFTR gene and is most relevant for people of Ashkenazi Jewish, European and Hispanic/Latino descent. The Sickle Cell Anemia Carrier Status test is indicated for the detection of the HbS variant in the HBB gene and is most relevant for people of African descent. The Carrier Status tests related to hereditary hearing loss consist of two tests — one indicated for the detection of two variants in the GJB2 gene, which is most relevant for people of Ashkenazi Jewish and European descent, and one indicated for the detection of six variants in the SLC26A4 gene.